Sanofi lifts forecast as blockbuster eczema drug gains

Dupixent, a blockbuster drug used to treat a number of ailments including asthma and eczema, is continuing to win in the US and Europe, as the French firm works to expand the drug’s label even further.


French drugmaker Sanofi raised its profit guidance as blockbuster therapy Dupixent expands its market share in the US and Europe.

Earnings per share, excluding some items, will grow by about 15% at constant currencies this year, the Paris-based company said Thursday. That compares with an earlier forecast of low double-digit growth. Sanofi shares rose as much as 2.2% in Paris trading.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs